{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:13:39Z","timestamp":1793963619220,"version":"4.8.0"},"reference-count":201,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103757"],"award-info":[{"award-number":["82103757"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073473"],"award-info":[{"award-number":["82073473"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pyroptosis, apoptosis, and necroptosis are mainly programmed cell death (PCD) pathways for host defense and homeostasis. PANoptosis is a newly distinct inflammatory PCD pathway that is uniquely regulated by multifaceted PANoptosome complexes and highlights significant crosstalk and coordination among pyroptosis (P), apoptosis (A), and\/or necroptosis(N). Although some studies have focused on the possible role of PANpoptosis in diseases, the pathogenesis of PANoptosis is complex and underestimated. Furthermore, the progress of PANoptosis and related agonists or inhibitors in disorders has not yet been thoroughly discussed. In this perspective, we provide perspectives on PANoptosome and PANoptosis in the context of diverse pathological conditions and human diseases. The treatment targeting on PANoptosis is also summarized. In conclusion, PANoptosis is involved in plenty of disorders including but not limited to microbial infections, cancers, acute lung injury\/acute respiratory distress syndrome (ALI\/ARDS), ischemia-reperfusion, and organic failure. PANoptosis seems to be a double-edged sword in diverse conditions, as PANoptosis induces a negative impact on treatment and prognosis in disorders like COVID-19 and ALI\/ARDS, while PANoptosis provides host protection from HSV1 or\n                    <jats:italic>Francisella novicida<\/jats:italic>\n                    infection, and kills cancer cells and suppresses tumor growth in colorectal cancer, adrenocortical carcinoma, and other cancers. Compounds and endogenous molecules focused on PANoptosis are promising therapeutic strategies, which can act on PANoptosomes-associated members to regulate PANoptosis. More researches on PANoptosis are needed to better understand the pathology of human conditions and develop better treatment.\n                  <\/jats:p>","DOI":"10.1038\/s41419-023-06370-2","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:06:50Z","timestamp":1703117210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":189,"title":["Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8905-378X","authenticated-orcid":false,"given":"Lian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanghui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoping","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5109-6055","authenticated-orcid":false,"given":"Xian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0042-8456","authenticated-orcid":false,"given":"Fengbo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-8882","authenticated-orcid":false,"given":"Gu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"6370_CR1","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41580-020-0270-8","volume":"21","author":"S Bedoui","year":"2020","unstructured":"Bedoui S, Herold MJ, Strasser A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat Rev Mol Cell Biol. 2020;21:678\u201395.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6370_CR2","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","volume":"18","author":"D Bertheloot","year":"2021","unstructured":"Bertheloot D, Latz E, Franklin BS. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell Mol Immunol. 2021;18:1106\u201321.","journal-title":"Cell Mol Immunol"},{"key":"6370_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ymeth.2013.02.011","volume":"61","author":"T Vanden Berghe","year":"2013","unstructured":"Vanden Berghe T, Grootjans S, Goossens V, Dondelinger Y, Krysko DV, Takahashi N, et al. Determination of apoptotic and necrotic cell death in vitro and in vivo. Methods. 2013;61:117\u201329.","journal-title":"Methods"},{"key":"6370_CR4","doi-asserted-by":"publisher","first-page":"701564","DOI":"10.3389\/fphar.2021.701564","volume":"12","author":"Z Yu","year":"2021","unstructured":"Yu Z, Jiang N, Su W, Zhuo Y. Necroptosis: a novel pathway in neuroinflammation. Front Pharm. 2021;12:701564.","journal-title":"Front Pharm"},{"key":"6370_CR5","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3389\/fcimb.2019.00406","volume":"9","author":"RKS Malireddi","year":"2019","unstructured":"Malireddi RKS, Kesavardhana S, Kanneganti TD. ZBP1 and TAK1: master regulators of NLRP3 inflammasome\/pyroptosis, apoptosis, and necroptosis (PAN-optosis). Front Cell Infect Microbiol. 2019;9:406.","journal-title":"Front Cell Infect Microbiol"},{"key":"6370_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fcimb.2020.00237","volume":"10","author":"S Christgen","year":"2020","unstructured":"Christgen S, Zheng M, Kesavardhana S, Karki R, Malireddi RKS, Banoth B, et al. Identification of the PANoptosome: a molecular platform triggering pyroptosis, apoptosis, and necroptosis (PANoptosis). Front Cell Infect Microbiol. 2020;10:237.","journal-title":"Front Cell Infect Microbiol"},{"key":"6370_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-021-03875-8","volume":"597","author":"S Lee","year":"2021","unstructured":"Lee S, Karki R. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence. Nature. 2021;597:415\u201319.","journal-title":"Nature"},{"key":"6370_CR8","doi-asserted-by":"publisher","first-page":"e136720","DOI":"10.1172\/jci.insight.136720","volume":"5","author":"R Karki","year":"2020","unstructured":"Karki R, Sharma BR, Lee E, Banoth B, Malireddi RKS, Samir P, et al. Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer. JCI insight. 2020;5:e136720.","journal-title":"JCI insight"},{"key":"6370_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.mib.2020.07.012","volume":"59","author":"DE Place","year":"2021","unstructured":"Place DE, Lee S, Kanneganti TD. PANoptosis in microbial infection. Curr Opin Microbiol. 2021;59:42\u20139.","journal-title":"Curr Opin Microbiol"},{"key":"6370_CR10","doi-asserted-by":"publisher","first-page":"789610","DOI":"10.3389\/fimmu.2021.789610","volume":"12","author":"W Jiang","year":"2021","unstructured":"Jiang W, Deng Z, Dai X, Zhao W. PANoptosis: a new insight into oral infectious diseases. Front Immunol. 2021;12:789610.","journal-title":"Front Immunol"},{"key":"6370_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00018-022-04564-z","volume":"79","author":"Y Wang","year":"2022","unstructured":"Wang Y, Pandian N, Han JH, Sundaram B, Lee S, Karki R, et al. Single cell analysis of PANoptosome cell death complexes through an expansion microscopy method. Cell Mol Life Sci. 2022;79:531.","journal-title":"Cell Mol Life Sci"},{"key":"6370_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fcimb.2020.00238","volume":"10","author":"P Samir","year":"2020","unstructured":"Samir P, Malireddi RKS, Kanneganti TD. The PANoptosome: a deadly protein complex driving pyroptosis, apoptosis, and necroptosis (PANoptosis). Front Cell Infect Microbiol. 2020;10:238.","journal-title":"Front Cell Infect Microbiol"},{"key":"6370_CR13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.4049\/immunohorizons.2000097","volume":"4","author":"RKS Malireddi","year":"2020","unstructured":"Malireddi RKS, Kesavardhana S, Karki R, Kancharana B, Burton AR, Kanneganti TD. RIPK1 distinctly regulates yersinia-induced inflammatory cell death, PANoptosis. Immunohorizons. 2020;4:789\u201396.","journal-title":"Immunohorizons"},{"key":"6370_CR14","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/j.cell.2023.05.005","volume":"186","author":"B Sundaram","year":"2023","unstructured":"Sundaram B, Pandian N, Mall R, Wang Y, Sarkar R, Kim HJ, et al. NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs. Cell. 2023;186:2783\u2013801.e20.","journal-title":"Cell"},{"key":"6370_CR15","doi-asserted-by":"publisher","first-page":"102348","DOI":"10.1016\/j.coi.2023.102348","volume":"83","author":"R Karki","year":"2023","unstructured":"Karki R, Kanneganti TD. PANoptosome signaling and therapeutic implications in infection: central role for ZBP1 to activate the inflammasome and PANoptosis. Curr Opin Immunol. 2023;83:102348.","journal-title":"Curr Opin Immunol"},{"key":"6370_CR16","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.cell.2020.03.040","volume":"181","author":"M Zheng","year":"2020","unstructured":"Zheng M, Karki R, Vogel P, Kanneganti TD. Caspase-6 is a key regulator of innate immunity, inflammasome activation, and host defense. Cell. 2020;181:674\u201387.e13.","journal-title":"Cell"},{"key":"6370_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.it.2017.11.002","volume":"39","author":"T Kuriakose","year":"2018","unstructured":"Kuriakose T, Kanneganti TD. ZBP1: innate sensor regulating cell death and inflammation. Trends Immunol. 2018;39:123\u201334.","journal-title":"Trends Immunol"},{"key":"6370_CR18","doi-asserted-by":"publisher","first-page":"eabo6294","DOI":"10.1126\/sciimmunol.abo6294","volume":"7","author":"R Karki","year":"2022","unstructured":"Karki R, Lee S. ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection. Sci Immunol. 2022;7:eabo6294.","journal-title":"Sci Immunol"},{"key":"6370_CR19","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1016\/j.cell.2023.05.039","volume":"186","author":"Y Lei","year":"2023","unstructured":"Lei Y, VanPortfliet JJ, Chen YF, Bryant JD, Li Y, Fails D, et al. Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity. Cell. 2023;186:3013\u201332.e22.","journal-title":"Cell"},{"key":"6370_CR20","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/embor.2009.109","volume":"10","author":"M Rebsamen","year":"2009","unstructured":"Rebsamen M, Heinz LX, Meylan E, Michallet MC, Schroder K, Hofmann K, et al. DAI\/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-kappaB. EMBO Rep. 2009;10:916\u201322.","journal-title":"EMBO Rep."},{"key":"6370_CR21","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41586-022-04878-9","volume":"607","author":"H Jiao","year":"2022","unstructured":"Jiao H, Wachsmuth L, Wolf S, Lohmann J, Nagata M, Kaya GG, et al. ADAR1 averts fatal type I interferon induction by ZBP1. Nature. 2022;607:776\u201383.","journal-title":"Nature"},{"key":"6370_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1761-4","volume":"10","author":"L Sun","year":"2019","unstructured":"Sun L, Ma W, Gao W, Xing Y, Chen L, Xia Z, et al. Propofol directly induces caspase-1-dependent macrophage pyroptosis through the NLRP3-ASC inflammasome. Cell Death Dis. 2019;10:542.","journal-title":"Cell Death Dis"},{"key":"6370_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41586-019-1770-6","volume":"575","author":"M Fritsch","year":"2019","unstructured":"Fritsch M, G\u00fcnther SD, Schwarzer R, Albert MC, Schorn F, Werthenbach JP, et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature. 2019;575:683\u201387.","journal-title":"Nature"},{"key":"6370_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.4049\/immunohorizons.2100059","volume":"5","author":"RKS Malireddi","year":"2021","unstructured":"Malireddi RKS, Karki R, Sundaram B, Kancharana B, Lee S, Samir P. Inflammatory cell death, PANoptosis, mediated by cytokines in diverse cancer lineages inhibits tumor growth. Immunohorizons. 2021;5:568\u201380.","journal-title":"Immunohorizons"},{"key":"6370_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","volume":"184","author":"R Karki","year":"2021","unstructured":"Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, et al. Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell. 2021;184:149\u201368.e17.","journal-title":"Cell"},{"key":"6370_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature06013","volume":"448","author":"A Takaoka","year":"2007","unstructured":"Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, et al. DAI (DLM-1\/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature. 2007;448:501\u20135.","journal-title":"Nature"},{"key":"6370_CR27","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.4049\/jimmunol.1701538","volume":"200","author":"T Kuriakose","year":"2018","unstructured":"Kuriakose T, Zheng M. IRF1 is a transcriptional regulator of ZBP1 promoting NLRP3 inflammasome activation and cell death during influenza virus infection. J Immunol. 2018;200:1489\u201395.","journal-title":"J Immunol"},{"key":"6370_CR28","doi-asserted-by":"publisher","first-page":"105141","DOI":"10.1016\/j.jbc.2023.105141","volume":"299","author":"BR Sharma","year":"2023","unstructured":"Sharma BR, Karki R, Rajesh Y, Kanneganti TD. Immune regulator IRF1 contributes to ZBP1-, AIM2-, RIPK1-, and NLRP12-PANoptosome activation and inflammatory cell death (PANoptosis). J Biol Chem. 2023;299:105141.","journal-title":"J Biol Chem"},{"key":"6370_CR29","doi-asserted-by":"publisher","first-page":"e0061522","DOI":"10.1128\/mbio.00615-22","volume":"13","author":"R Gui","year":"2022","unstructured":"Gui R, Zheng H, Ma L, Liu R, Lin X, Ke X, et al. Sperm-associated antigen 9 promotes influenza A virus-induced cell death via the c-Jun N-terminal kinase signaling pathway. MBio. 2022;13:e0061522.","journal-title":"MBio"},{"key":"6370_CR30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nature07710","volume":"458","author":"T Fernandes-Alnemri","year":"2009","unstructured":"Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature. 2009;458:509\u201313.","journal-title":"Nature"},{"key":"6370_CR31","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.immuni.2020.04.010","volume":"52","author":"B Tummers","year":"2020","unstructured":"Tummers B, Mari L, Guy CS, Heckmann BL, Rodriguez DA, R\u00fchl S, et al. Caspase-8-dependent inflammatory responses are controlled by its adaptor, FADD, and necroptosis. Immunity. 2020;52:994\u20131006.e8.","journal-title":"Immunity"},{"key":"6370_CR32","doi-asserted-by":"publisher","first-page":"e2207240119","DOI":"10.1073\/pnas.2207240119","volume":"119","author":"DA Rodriguez","year":"2022","unstructured":"Rodriguez DA, Quarato G. Caspase-8 and FADD prevent spontaneous ZBP1 expression and necroptosis. Proc Natl Acad Sci USA. 2022;119:e2207240119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6370_CR33","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.immuni.2020.04.002","volume":"52","author":"R Schwarzer","year":"2020","unstructured":"Schwarzer R, Jiao H, Wachsmuth L, Tresch A, Pasparakis M. FADD and caspase-8 regulate gut homeostasis and inflammation by controlling MLKL- and GSDMD-mediated death of intestinal epithelial cells. Immunity. 2020;52:978\u201393.e6.","journal-title":"Immunity"},{"key":"6370_CR34","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/ni.3118","volume":"16","author":"SM Man","year":"2015","unstructured":"Man SM, Karki R, Malireddi RK, Neale G, Vogel P, Yamamoto M, et al. The transcription factor IRF1 and guanylate-binding proteins target activation of the AIM2 inflammasome by Francisella infection. Nat Immunol. 2015;16:467\u201375.","journal-title":"Nat Immunol"},{"key":"6370_CR35","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/ni.3206","volume":"16","author":"J Silke","year":"2015","unstructured":"Silke J, Rickard JA, Gerlic M. The diverse role of RIP kinases in necroptosis and inflammation. Nat Immunol. 2015;16:689\u201397.","journal-title":"Nat Immunol"},{"key":"6370_CR36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.immuni.2012.07.006","volume":"37","author":"GI Vladimer","year":"2012","unstructured":"Vladimer GI, Weng D, Paquette SW, Vanaja SK, Rathinam VA, Aune MH, et al. The NLRP12 inflammasome recognizes Yersinia pestis. Immunity. 2012;37:96\u2013107.","journal-title":"Immunity"},{"key":"6370_CR37","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.immuni.2012.03.012","volume":"36","author":"IC Allen","year":"2012","unstructured":"Allen IC, Wilson JE, Schneider M, Lich JD, Roberts RA, Arthur JC, et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-\u03baB signaling. Immunity. 2012;36:742\u201354.","journal-title":"Immunity"},{"key":"6370_CR38","doi-asserted-by":"publisher","first-page":"e166295","DOI":"10.1172\/JCI166295","volume":"133","author":"S Khan","year":"2023","unstructured":"Khan S, Kwak YT, Peng L, Hu S, Cantarel BL, Lewis CM, et al. NLRP12 downregulates the Wnt\/\u03b2-catenin pathway via interaction with STK38 to suppress colorectal cancer. J Clin Invest. 2023;133:e166295.","journal-title":"J Clin Invest"},{"key":"6370_CR39","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/jmv.25965","volume":"92","author":"J Liu","year":"2020","unstructured":"Liu J, Liu S. The management of coronavirus disease 2019 (COVID-19). J Med Virol. 2020;92:1484\u201390.","journal-title":"J Med Virol"},{"key":"6370_CR40","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/joim.13184","volume":"289","author":"AY Chang","year":"2021","unstructured":"Chang AY, Cullen MR, Harrington RA, Barry M. The impact of novel coronavirus COVID-19 on noncommunicable disease patients and health systems: a review. J Intern Med. 2021;289:450\u201362.","journal-title":"J Intern Med"},{"key":"6370_CR41","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/cid\/ciac635","volume":"76","author":"T Arashiro","year":"2023","unstructured":"Arashiro T, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, et al. Coronavirus disease 19 (COVID-19) vaccine effectiveness against symptomatic severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection during delta-dominant and omicron-dominant periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study). Clin Infect Dis. 2023;76:e108\u201315.","journal-title":"Clin Infect Dis"},{"key":"6370_CR42","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12929-022-00852-9","volume":"29","author":"M Kumari","year":"2022","unstructured":"Kumari M, Lu RM, Li MC, Huang JL, Hsu FF, Ko SH, et al. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. J Biomed Sci. 2022;29:68.","journal-title":"J Biomed Sci"},{"key":"6370_CR43","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.it.2020.10.005","volume":"41","author":"S Lee","year":"2020","unstructured":"Lee S, Channappanavar R, Kanneganti TD. Coronaviruses: innate immunity, inflammasome activation, inflammatory cell death, and cytokines. Trends Immunol. 2020;41:1083\u201399.","journal-title":"Trends Immunol"},{"key":"6370_CR44","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, M\u00f8ller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:1036\u201345.e9.","journal-title":"Cell"},{"key":"6370_CR45","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1126\/science.abc6261","volume":"369","author":"PS Arunachalam","year":"2020","unstructured":"Arunachalam PS, Wimmers F. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. 2020;369:1210\u201320.","journal-title":"Science"},{"key":"6370_CR46","doi-asserted-by":"publisher","first-page":"aag2045","DOI":"10.1126\/sciimmunol.aag2045","volume":"1","author":"T Kuriakose","year":"2016","unstructured":"Kuriakose T, Man SM, Malireddi RK, Karki R, Kesavardhana S, Place DE, et al. ZBP1\/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. Sci Immunol. 2016;1:aag2045.","journal-title":"Sci Immunol"},{"key":"6370_CR47","doi-asserted-by":"publisher","first-page":"8325","DOI":"10.1074\/jbc.RA120.013752","volume":"295","author":"S Kesavardhana","year":"2020","unstructured":"Kesavardhana S, Malireddi RKS, Burton AR, Porter SN, Vogel P, Pruett-Miller SM, et al. The Z\u03b12 domain of ZBP1 is a molecular switch regulating influenza-induced PANoptosis and perinatal lethality during development. J Biol Chem. 2020;295:8325\u201330.","journal-title":"J Biol Chem"},{"key":"6370_CR48","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.micinf.2019.06.007","volume":"21","author":"C Demeure","year":"2019","unstructured":"Demeure C, Dussurget O, Fiol GM, Le Guern AS, Savin C, Pizarro-Cerd\u00e1 J. Yersinia pestis and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination and diagnostics. Microbes Infect. 2019;21:202\u201312.","journal-title":"Microbes Infect"},{"key":"6370_CR49","doi-asserted-by":"publisher","first-page":"jem.20191644","DOI":"10.1084\/jem.20191644","volume":"217","author":"RKS Malireddi","year":"2020","unstructured":"Malireddi RKS, Gurung P, Kesavardhana S, Samir P, Burton A, Mummareddy H, et al. Innate immune priming in the absence of TAK1 drives RIPK1 kinase activity-independent pyroptosis, apoptosis, necroptosis, and inflammatory disease. J Exp Med. 2020;217:jem.20191644.","journal-title":"J Exp Med"},{"key":"6370_CR50","doi-asserted-by":"publisher","first-page":"720147","DOI":"10.3389\/fcimb.2021.720147","volume":"11","author":"D Chi","year":"2021","unstructured":"Chi D, Lin X, Meng Q, Tan J, Gong Q, Tong Z. Real-time induction of macrophage apoptosis, pyroptosis, and necroptosis by Enterococcus faecalis OG1RF and two root canal isolated strains. Front Cell Infect Microbiol. 2021;11:720147.","journal-title":"Front Cell Infect Microbiol"},{"key":"6370_CR51","doi-asserted-by":"publisher","first-page":"e0105921","DOI":"10.1128\/mBio.01059-21","volume":"12","author":"DE Place","year":"2021","unstructured":"Place DE, Christgen S, Tuladhar S, Vogel P, Malireddi RKS, Kanneganti TD. Hierarchical cell death program disrupts the intracellular niche required for Burkholderia thailandensis pathogenesis. mBio. 2021;12:e0105921.","journal-title":"mBio"},{"key":"6370_CR52","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1097\/CM9.0000000000002010","volume":"135","author":"R Zhou","year":"2022","unstructured":"Zhou R, Ying J, Qiu X, Yu L, Yue Y, Liu Q, et al. A new cell death program regulated by toll-like receptor 9 through p38 mitogen-activated protein kinase signaling pathway in a neonatal rat model with sepsis associated encephalopathy. Chin Med J. 2022;135:1474\u201385.","journal-title":"Chin Med J"},{"key":"6370_CR53","doi-asserted-by":"publisher","first-page":"18276","DOI":"10.1074\/jbc.RA120.015924","volume":"295","author":"B Banoth","year":"2020","unstructured":"Banoth B, Tuladhar S, Karki R, Sharma BR, Briard B, Kesavardhana S, et al. ZBP1 promotes fungi-induced inflammasome activation and pyroptosis, apoptosis, and necroptosis (PANoptosis). J Biol Chem. 2020;295:18276\u201383.","journal-title":"J Biol Chem"},{"key":"6370_CR54","first-page":"316","volume":"4","author":"B Briard","year":"2019","unstructured":"Briard B, Karki R. Fungal ligands released by innate immune effectors promote inflammasome activation during Aspergillus fumigatus infection. J Biol Chem. 2019;4:316\u201327.","journal-title":"J Biol Chem"},{"key":"6370_CR55","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/ijc.33698","volume":"149","author":"M Jiang","year":"2021","unstructured":"Jiang M, Qi L, Li L, Wu Y, Song D, Li Y, et al. key protein of cross-talk signal way in \u201cPANoptosis\u201d in cancer. Int J Cancer. 2021;149:1408\u201320.","journal-title":"Int J Cancer"},{"key":"6370_CR56","doi-asserted-by":"publisher","first-page":"109019","DOI":"10.1016\/j.clim.2022.109019","volume":"238","author":"H Pan","year":"2022","unstructured":"Pan H, Pan J, Li P, Gao J. Characterization of PANoptosis patterns predicts survival and immunotherapy response in gastric cancer. Clin Immunol. 2022;238:109019.","journal-title":"Clin Immunol"},{"key":"6370_CR57","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467\u201380.","journal-title":"Lancet"},{"key":"6370_CR58","doi-asserted-by":"publisher","first-page":"955355","DOI":"10.3389\/fgene.2022.955355","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, Sun R, Chan S, Meng L, Xu Y, Zuo X, et al. PANoptosis-based molecular clustering and prognostic signature predicts patient survival and immune landscape in colon cancer. Front Genet. 2022;13:955355.","journal-title":"Front Genet"},{"key":"6370_CR59","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/sj.onc.1207023","volume":"23","author":"PK Kim","year":"2004","unstructured":"Kim PK, Armstrong M, Liu Y, Yan P, Bucher B, Zuckerbraun BS, et al. IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo. Oncogene. 2004;23:1125\u201335.","journal-title":"Oncogene"},{"key":"6370_CR60","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41392-022-00889-0","volume":"7","author":"JF Lin","year":"2022","unstructured":"Lin JF, Hu PS, Wang YY, Tan YT, Yu K, Liao K, et al. Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis. Signal Transduct Target Ther. 2022;7:54.","journal-title":"Signal Transduct Target Ther"},{"key":"6370_CR61","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1074\/jbc.TM118.004166","volume":"294","author":"CE Samuel","year":"2019","unstructured":"Samuel CE. Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA-triggered innate immune responses. J Biol Chem. 2019;294:1710\u201320.","journal-title":"J Biol Chem"},{"key":"6370_CR62","doi-asserted-by":"publisher","first-page":"109858","DOI":"10.1016\/j.celrep.2021.109858","volume":"37","author":"R Karki","year":"2021","unstructured":"Karki R, Sundaram B, Sharma BR, Lee S, Malireddi RKS, Nguyen LN, et al. ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis. Cell Rep. 2021;37:109858.","journal-title":"Cell Rep."},{"key":"6370_CR63","doi-asserted-by":"publisher","first-page":"888105","DOI":"10.3389\/fonc.2022.888105","volume":"12","author":"J Huang","year":"2022","unstructured":"Huang J, Jiang S, Liang L, He H, Liu Y, Cong L, et al. Analysis of PANoptosis-related LncRNA-miRNA-mRNA network reveals LncRNA SNHG7 involved in chemo-resistance in colon adenocarcinoma. Front Oncol. 2022;12:888105.","journal-title":"Front Oncol"},{"key":"6370_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03641-y","volume":"20","author":"L Ren","year":"2022","unstructured":"Ren L, Yang Y, Li W, Zheng X, Liu J, Li S, et al. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2\/M phase transition, and PANoptosis. J Transl Med. 2022;20:444.","journal-title":"J Transl Med"},{"key":"6370_CR65","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/10717544.2021.1898703","volume":"28","author":"M Song","year":"2021","unstructured":"Song M, Xia W, Tao Z, Zhu B, Zhang W, Liu C, et al. Self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy. Drug Deliv. 2021;28:594\u2013606.","journal-title":"Drug Deliv"},{"key":"6370_CR66","doi-asserted-by":"publisher","first-page":"zcac033","DOI":"10.1093\/narcan\/zcac033","volume":"4","author":"R Mall","year":"2022","unstructured":"Mall R, Bynigeri RR, Karki R, Malireddi RKS, Sharma BR, Kanneganti TD. Pancancer transcriptomic profiling identifies key PANoptosis markers as therapeutic targets for oncology. NAR Cancer. 2022;4:zcac033.","journal-title":"NAR Cancer"},{"key":"6370_CR67","doi-asserted-by":"publisher","first-page":"345","DOI":"10.5858\/arpa.2015-0519-RA","volume":"140","author":"Y Butt","year":"2016","unstructured":"Butt Y, Kurdowska A, Allen TC. Acute lung injury: a clinical and molecular review. Arch Pathol Lab Med. 2016;140:345\u201350.","journal-title":"Arch Pathol Lab Med"},{"key":"6370_CR68","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0140-6736(21)00439-6","volume":"398","author":"NJ Meyer","year":"2021","unstructured":"Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. Lancet. 2021;398:622\u201337.","journal-title":"Lancet"},{"key":"6370_CR69","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5694\/mja2.50674","volume":"213","author":"PG Gibson","year":"2020","unstructured":"Gibson PG, Qin L, Puah SH. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. Med J Aust. 2020;213:54\u201356.e1.","journal-title":"Med J Aust"},{"key":"6370_CR70","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.3390\/jcm9103323","volume":"9","author":"L Motedayen Aval","year":"2020","unstructured":"Motedayen Aval L, Pease JE, Sharma R, Pinato DJ. Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy. J Clin Med. 2020;9:3323.","journal-title":"J Clin Med"},{"key":"6370_CR71","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","volume":"6","author":"JW Schoggins","year":"2019","unstructured":"Schoggins JW. Interferon-stimulated genes: what do they all do? Annu Rev Virol. 2019;6:567\u201384.","journal-title":"Annu Rev Virol"},{"key":"6370_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04664-5","volume":"13","author":"Y Messaoud-Nacer","year":"2022","unstructured":"Messaoud-Nacer Y, Culerier E, Rose S, Maillet I, Rouxel N, Briault S, et al. STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS). Cell Death Dis. 2022;13:269.","journal-title":"Cell Death Dis"},{"key":"6370_CR73","doi-asserted-by":"publisher","first-page":"899","DOI":"10.14336\/AD.2021.1023","volume":"13","author":"Y Cui","year":"2022","unstructured":"Cui Y, Wang X, Lin F, Li W, Zhao Y, Zhu F, et al. MiR-29a-3p improves acute lung injury by reducing alveolar epithelial cell PANoptosis. Aging Dis. 2022;13:899\u2013909.","journal-title":"Aging Dis"},{"key":"6370_CR74","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/med.21398","volume":"36","author":"BW Ke","year":"2016","unstructured":"Ke BW, Tian M, Li JJ, Liu B, He G. Targeting programmed cell death using small-molecule compounds to improve potential cancer therapy. Med Res Rev. 2016;36:983\u20131035.","journal-title":"Med Res Rev"},{"key":"6370_CR75","doi-asserted-by":"publisher","first-page":"628988","DOI":"10.3389\/fphar.2021.628988","volume":"12","author":"Z Fan","year":"2021","unstructured":"Fan Z, Cai L, Wang S, Wang J, Chen B. Baicalin prevents myocardial ischemia\/reperfusion injury through inhibiting ACSL4 mediated ferroptosis. Front Pharm. 2021;12:628988.","journal-title":"Front Pharm"},{"key":"6370_CR76","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1038\/s41418-020-0528-x","volume":"27","author":"Y Li","year":"2020","unstructured":"Li Y, Cao Y, Xiao J, Shang J, Tan Q, Ping F, et al. Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia\/reperfusion-induced acute lung injury. Cell Death Differ. 2020;27:2635\u201350.","journal-title":"Cell Death Differ"},{"key":"6370_CR77","doi-asserted-by":"publisher","first-page":"101836","DOI":"10.1016\/j.redox.2020.101836","volume":"39","author":"G Zhang","year":"2021","unstructured":"Zhang G, Han H, Zhuge Z, Dong F, Jiang S, Wang W, et al. Renovascular effects of inorganic nitrate following ischemia-reperfusion of the kidney. Redox Biol. 2021;39:101836.","journal-title":"Redox Biol"},{"key":"6370_CR78","doi-asserted-by":"publisher","first-page":"934154","DOI":"10.3389\/fgene.2022.934154","volume":"13","author":"J Shu","year":"2022","unstructured":"Shu J, Yang L, Wei W, Zhang L. Identification of programmed cell death-related gene signature and associated regulatory axis in cerebral ischemia\/reperfusion injury. Front Genet. 2022;13:934154.","journal-title":"Front Genet"},{"key":"6370_CR79","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.4103\/1673-5374.331539","volume":"17","author":"WT Yan","year":"2022","unstructured":"Yan WT, Yang YD, Hu XM, Ning WY, Liao LS, Lu S, et al. Do pyroptosis, apoptosis, and necroptosis (PANoptosis) exist in cerebral ischemia? Evidence from cell and rodent studies. Neural Regen Res. 2022;17:1761\u201368.","journal-title":"Neural Regen Res"},{"key":"6370_CR80","doi-asserted-by":"publisher","first-page":"1004163","DOI":"10.3389\/fgene.2022.1004163","volume":"13","author":"J Li","year":"2022","unstructured":"Li J, Zhang X, Ren P, Wu Y, Wang Y, Zhou W, et al. Landscape of RNA-binding proteins in diagnostic utility, immune cell infiltration and PANoptosis features of heart failure. Front Genet. 2022;13:1004163.","journal-title":"Front Genet"},{"key":"6370_CR81","first-page":"357","volume":"18","author":"WT Yan","year":"2023","unstructured":"Yan WT, Zhao WJ, Hu XM, Ban XX, Ning WY, Wan H, et al. PANoptosis-like cell death in ischemia\/reperfusion injury of retinal neurons. Neural Regen Res. 2023;18:357\u201363.","journal-title":"Neural Regen Res"},{"key":"6370_CR82","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1080\/08941939.2022.2128117","volume":"35","author":"E Uysal","year":"2022","unstructured":"Uysal E, Dokur M, Kucukdurmaz F, Alt\u0131nay S, Polat S, Batc\u0131oglu K, et al. Targeting the PANoptosome with 3,4-methylenedioxy-\u03b2-nitrostyrene, reduces PANoptosis and protects the kidney against renal i\u0307schemia-reperfusion injury. J Invest Surg. 2022;35:1824\u201335.","journal-title":"J Invest Surg"},{"key":"6370_CR83","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S2213-8587(18)30128-1","volume":"7","author":"C Sabanayagam","year":"2019","unstructured":"Sabanayagam C, Banu R, Chee ML, Lee R, Wang YX, Tan G, et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol. 2019;7:140\u201349.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6370_CR84","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbrc.2022.05.001","volume":"617","author":"X Xu","year":"2022","unstructured":"Xu X, Lan X, Fu S, Zhang Q, Gui F, Jin Q, et al. Dickkopf-1 exerts protective effects by inhibiting PANoptosis and retinal neovascularization in diabetic retinopathy. Biochem Biophys Res Commun. 2022;617:69\u201376.","journal-title":"Biochem Biophys Res Commun"},{"key":"6370_CR85","doi-asserted-by":"publisher","first-page":"102687","DOI":"10.1016\/j.redox.2023.102687","volume":"62","author":"Z Zeng","year":"2023","unstructured":"Zeng Z, You M, Fan C, Rong R, Li H, Xia X. Pathologically high intraocular pressure induces mitochondrial dysfunction through Drp1 and leads to retinal ganglion cell PANoptosis in glaucoma. Redox Biol. 2023;62:102687.","journal-title":"Redox Biol"},{"key":"6370_CR86","doi-asserted-by":"publisher","first-page":"e12828","DOI":"10.1111\/jpi.12828","volume":"73","author":"D Ye","year":"2022","unstructured":"Ye D, Xu Y, Shi Y, Fan M, Lu P, Bai X, et al. Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model. J Pineal Res. 2022;73:e12828.","journal-title":"J Pineal Res"},{"key":"6370_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05460-x","volume":"13","author":"Y Bi","year":"2022","unstructured":"Bi Y, Xu H, Wang X, Zhu H, Ge J, Ren J, et al. FUNDC1 protects against doxorubicin-induced cardiomyocyte PANoptosis through stabilizing mtDNA via interaction with TUFM. Cell Death Dis. 2022;13:1020.","journal-title":"Cell Death Dis"},{"key":"6370_CR88","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nri.2015.7","volume":"16","author":"SM Man","year":"2016","unstructured":"Man SM, Kanneganti TD. Converging roles of caspases in inflammasome activation, cell death and innate immunity. Nat Rev Immunol. 2016;16:7\u201321.","journal-title":"Nat Rev Immunol"},{"key":"6370_CR89","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.4049\/jimmunol.175.4.2630","volume":"175","author":"JH Stack","year":"2005","unstructured":"Stack JH, Beaumont K, Larsen PD, Straley KS, Henkel GW, Randle JC, et al. IL-converting enzyme\/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol. 2005;175:2630\u20134.","journal-title":"J Immunol"},{"key":"6370_CR90","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1164\/rccm.202005-1916OC","volume":"204","author":"K Peukert","year":"2021","unstructured":"Peukert K, Fox M, Schulz S, Feuerborn C, Frede S, Putensen C, et al. Inhibition of caspase-1 with tetracycline ameliorates acute lung injury. Am J Respir Crit Care Med. 2021;204:53\u201363.","journal-title":"Am J Respir Crit Care Med"},{"key":"6370_CR91","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1111\/bph.15076","volume":"177","author":"Y Tang","year":"2020","unstructured":"Tang Y, Feng B, Wang Y, Sun H, You Y, Yu J, et al. Structure-based discovery of CZL80, a caspase-1 inhibitor with therapeutic potential for febrile seizures and later enhanced epileptogenic susceptibility. Br J Pharm. 2020;177:3519\u201334.","journal-title":"Br J Pharm"},{"key":"6370_CR92","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/40657","volume":"388","author":"M Irmler","year":"1997","unstructured":"Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190\u20135.","journal-title":"Nature"},{"key":"6370_CR93","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll RC, Robertson AA, Chae JJ, Higgins SC, Mu\u00f1oz-Planillo R, Inserra MC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21:248\u201355.","journal-title":"Nat Med"},{"key":"6370_CR94","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd.2018.97","volume":"17","author":"MSJ Mangan","year":"2018","unstructured":"Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov. 2018;17:588\u2013606.","journal-title":"Nat Rev Drug Discov"},{"key":"6370_CR95","doi-asserted-by":"publisher","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","volume":"115","author":"C Marchetti","year":"2018","unstructured":"Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, et al. OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci USA. 2018;115:E1530\u2013e39.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6370_CR96","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13075-018-1664-2","volume":"20","author":"C Marchetti","year":"2018","unstructured":"Marchetti C, Swartzwelter B, Koenders MI, Azam T, Tengesdal IW, Powers N, et al. NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Res Ther. 2018;20:169.","journal-title":"Arthritis Res Ther"},{"key":"6370_CR97","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/FJC.0000000000000931","volume":"77","author":"GF Wohlford","year":"2020","unstructured":"Wohlford GF, Van Tassell BW, Billingsley HE, Kadariya D, Canada JM, Carbone S, et al. Phase 1B, randomized, double-blinded, dose escalation, single-center, repeat dose safety and pharmacodynamics study of the oral NLRP3 inhibitor Dapansutrile in subjects with NYHA II-III systolic heart failure. J Cardiovasc Pharm. 2020;77:49\u201360.","journal-title":"J Cardiovasc Pharm"},{"key":"6370_CR98","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1083\/jcb.200903124","volume":"187","author":"M Lamkanfi","year":"2009","unstructured":"Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, et al. Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome. J Cell Biol. 2009;187:61\u201370.","journal-title":"J Cell Biol"},{"key":"6370_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9977","volume":"6","author":"J Liao","year":"2015","unstructured":"Liao J, Kapadia VS, Brown LS, Cheong N, Longoria C, Mija D, et al. The NLRP3 inflammasome is critically involved in the development of bronchopulmonary dysplasia. Nat Commun. 2015;6:8977.","journal-title":"Nat Commun"},{"key":"6370_CR100","first-page":"737","volume":"11","author":"L Liu","year":"2017","unstructured":"Liu L, Dong Y, Ye M, Jin S, Yang J, Joosse ME, et al. The pathogenic role of NLRP3 inflammasome activation in inflammatory bowel diseases of both mice and humans. J Crohns Colitis. 2017;11:737\u201350.","journal-title":"J Crohns Colitis"},{"key":"6370_CR101","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/FJC.0000000000000053","volume":"63","author":"C Marchetti","year":"2014","unstructured":"Marchetti C, Chojnacki J, Toldo S, Mezzaroma E, Tranchida N, Rose SW, et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharm. 2014;63:316\u201322.","journal-title":"J Cardiovasc Pharm"},{"key":"6370_CR102","doi-asserted-by":"crossref","unstructured":"Guo C, Fulp JW, Jiang Y, Li X, Chojnacki JE, Wu J, et al. Development and characterization of a hydroxyl-sulfonamide analogue, 5-chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis. ACS Chem Neurosci. 2017;8:2194\u2013201.","DOI":"10.1021\/acschemneuro.7b00124"},{"key":"6370_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12504","volume":"7","author":"MJ Daniels","year":"2016","unstructured":"Daniels MJ, Rivers-Auty J, Schilling T, Spencer NG, Watremez W, Fasolino V, et al. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer\u2019s disease in rodent models. Nat Commun. 2016;7:12504.","journal-title":"Nat Commun"},{"key":"6370_CR104","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.immuni.2012.06.013","volume":"37","author":"V Compan","year":"2012","unstructured":"Compan V, Baroja-Mazo A, L\u00f3pez-Castej\u00f3n G, Gomez AI, Mart\u00ednez CM, Angosto D, et al. Cell volume regulation modulates NLRP3 inflammasome activation. Immunity. 2012;37:487\u2013500.","journal-title":"Immunity"},{"key":"6370_CR105","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1084\/jem.20171419","volume":"214","author":"H Jiang","year":"2017","unstructured":"Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017;214:3219\u201338.","journal-title":"J Exp Med"},{"key":"6370_CR106","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3858\/emm.2011.43.5.035","volume":"43","author":"BH Kim","year":"2011","unstructured":"Kim BH, Min YS, Choi JS, Baeg GH, Kim YS, Shin JW, et al. Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3\/STAT3 signaling. Exp Mol Med. 2011;43:313\u201321.","journal-title":"Exp Mol Med"},{"key":"6370_CR107","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/JID.2015.384","volume":"136","author":"HG Lee","year":"2016","unstructured":"Lee HG, Cho NC, Jeong AJ, Li YC, Rhie SJ, Choi JS, et al. Immunomodulatory activities of the benzoxathiole derivative BOT-4-one ameliorate pathogenic skin inflammation in mice. J Invest Dermatol. 2016;136:107\u201316.","journal-title":"J Invest Dermatol"},{"key":"6370_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15314-8","volume":"7","author":"DW Shim","year":"2017","unstructured":"Shim DW, Shin WY, Yu SH, Kim BH, Ye SK, Koppula S, et al. BOT-4-one attenuates NLRP3 inflammasome activation: NLRP3 alkylation leading to the regulation of its ATPase activity and ubiquitination. Sci Rep. 2017;7:15020.","journal-title":"Sci Rep."},{"key":"6370_CR109","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.bcp.2013.03.008","volume":"85","author":"W Liu","year":"2013","unstructured":"Liu W, Guo W, Wu J, Luo Q, Tao F, Gu Y, et al. A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem Pharm. 2013;85:1504\u201312.","journal-title":"Biochem Pharm"},{"key":"6370_CR110","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1074\/jbc.M113.515080","volume":"289","author":"Y He","year":"2014","unstructured":"He Y, Varadarajan S, Mu\u00f1oz-Planillo R, Burberry A, Nakamura Y, N\u00fa\u00f1ez G. 3,4-Methylenedioxy-\u03b2-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014;289:1142\u201350.","journal-title":"J Biol Chem"},{"key":"6370_CR111","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.chembiol.2017.08.011","volume":"24","author":"AG Baldwin","year":"2017","unstructured":"Baldwin AG, Rivers-Auty J, Daniels MJD, White CS, Schwalbe CH, Schilling T, et al. Boron-based inhibitors of the NLRP3 inflammasome. Cell Chem Biol. 2017;24:1321\u201335.e5.","journal-title":"Cell Chem Biol"},{"key":"6370_CR112","doi-asserted-by":"publisher","first-page":"9792","DOI":"10.1074\/jbc.M109.082305","volume":"285","author":"C Juliana","year":"2010","unstructured":"Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW, et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem. 2010;285:9792\u2013802.","journal-title":"J Biol Chem"},{"key":"6370_CR113","doi-asserted-by":"publisher","first-page":"10366","DOI":"10.1021\/jm501072b","volume":"57","author":"M Cocco","year":"2014","unstructured":"Cocco M, Garella D, Di Stilo A, Borretto E, Stevanato L, Giorgis M, et al. Electrophilic warhead-based design of compounds preventing NLRP3 inflammasome-dependent pyroptosis. J Med Chem. 2014;57:10366\u201382.","journal-title":"J Med Chem"},{"key":"6370_CR114","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/cmdc.201600055","volume":"11","author":"M Cocco","year":"2016","unstructured":"Cocco M, Miglio G, Giorgis M, Garella D, Marini E, Costale A, et al. Design, synthesis, and evaluation of acrylamide derivatives as direct NLRP3 inflammasome inhibitors. ChemMedChem. 2016;11:1790\u2013803.","journal-title":"ChemMedChem"},{"key":"6370_CR115","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1021\/acs.jmedchem.6b01624","volume":"60","author":"M Cocco","year":"2017","unstructured":"Cocco M, Pellegrini C, Mart\u00ednez-Banaclocha H, Giorgis M, Marini E, Costale A, et al. Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease. J Med Chem. 2017;60:3656\u201371.","journal-title":"J Med Chem"},{"key":"6370_CR116","doi-asserted-by":"publisher","first-page":"6496","DOI":"10.1021\/acs.orglett.6b03435","volume":"18","author":"AH Zhang","year":"2016","unstructured":"Zhang AH, Liu W, Jiang N, Xu Q, Tan RX. Spirodalesol, an NLRP3 inflammasome activation inhibitor. Org Lett. 2016;18:6496\u201399.","journal-title":"Org Lett"},{"key":"6370_CR117","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41583-018-0093-1","volume":"20","author":"J Yuan","year":"2019","unstructured":"Yuan J, Amin P, Ofengeim D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci. 2019;20:19\u201333.","journal-title":"Nat Rev Neurosci"},{"key":"6370_CR118","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41573-020-0071-y","volume":"19","author":"L Mifflin","year":"2020","unstructured":"Mifflin L, Ofengeim D, Yuan J. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020;19:553\u201371.","journal-title":"Nat Rev Drug Discov"},{"key":"6370_CR119","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.tips.2020.01.002","volume":"41","author":"S Martens","year":"2020","unstructured":"Martens S, Hofmans S, Declercq W, Augustyns K, Vandenabeele P. Inhibitors targeting RIPK1\/RIPK3: old and new drugs. Trends Pharm Sci. 2020;41:209\u201324.","journal-title":"Trends Pharm Sci"},{"key":"6370_CR120","doi-asserted-by":"publisher","first-page":"14971","DOI":"10.1021\/acs.jmedchem.2c01518","volume":"65","author":"K Shi","year":"2022","unstructured":"Shi K, Zhang J, Zhou E, Wang J, Wang Y. Small-molecule receptor-interacting protein 1 (RIP1) inhibitors as therapeutic agents for multifaceted diseases: current medicinal chemistry insights and emerging opportunities. J Med Chem. 2022;65:14971\u201399.","journal-title":"J Med Chem"},{"key":"6370_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0245-7","volume":"9","author":"S Martens","year":"2018","unstructured":"Martens S, Goossens V, Devisscher L, Hofmans S, Claeys P, Vuylsteke M, et al. RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680). Cell Death Dis. 2018;9:211.","journal-title":"Cell Death Dis"},{"key":"6370_CR122","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1016\/j.apsb.2022.03.020","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang X, Hua P, He CW, Chen MW. Non-apoptotic cell death-based cancer therapy: Molecular mechanism, pharmacological modulators, and nanomedicine. Acta Pharm Sin B. 2022;12:3567\u201393.","journal-title":"Acta Pharm Sin B"},{"key":"6370_CR123","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nchembio.83","volume":"4","author":"A Degterev","year":"2008","unstructured":"Degterev A, Hitomi J, Germscheid M, Ch\u2019en IL, Korkina O, Teng X, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4:313\u201321.","journal-title":"Nat Chem Biol"},{"key":"6370_CR124","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.bmcl.2006.11.056","volume":"17","author":"K Wang","year":"2007","unstructured":"Wang K, Li J, Degterev A, Hsu E, Yuan J, Yuan C. Structure-activity relationship analysis of a novel necroptosis inhibitor, Necrostatin-5. Bioorg Med Chem Lett. 2007;17:1455\u201365.","journal-title":"Bioorg Med Chem Lett"},{"key":"6370_CR125","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1016\/j.bmcl.2013.06.073","volume":"23","author":"Z Wu","year":"2013","unstructured":"Wu Z, Li Y, Cai Y, Yuan J, Yuan C. A novel necroptosis inhibitor-necrostatin-21 and its SAR study. Bioorg Med Chem Lett. 2013;23:4903\u20136.","journal-title":"Bioorg Med Chem Lett"},{"key":"6370_CR126","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000510864","volume":"106","author":"S Qiao","year":"2021","unstructured":"Qiao S, Zhao WJ, Li HQ, Ao GZ, An JZ, Wang C, et al. Necrostatin-1 analog DIMO exerts cardioprotective effect against ischemia reperfusion injury by suppressing necroptosis via autophagic pathway in rats. Pharmacology. 2021;106:189\u2013201.","journal-title":"Pharmacology"},{"key":"6370_CR127","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.celrep.2015.02.052","volume":"10","author":"M Najjar","year":"2015","unstructured":"Najjar M, Suebsuwong C, Ray SS, Thapa RJ, Maki JL, Nogusa S, et al. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Rep. 2015;10:1850\u201360.","journal-title":"Cell Rep."},{"key":"6370_CR128","doi-asserted-by":"publisher","first-page":"15009","DOI":"10.1038\/cddiscovery.2015.9","volume":"1","author":"SB Berger","year":"2015","unstructured":"Berger SB, Harris P, Nagilla R, Kasparcova V, Hoffman S, Swift B, et al. Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase. Cell Death Discov. 2015;1:15009.","journal-title":"Cell Death Discov"},{"key":"6370_CR129","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1021\/acsmedchemlett.9b00108","volume":"10","author":"PA Harris","year":"2019","unstructured":"Harris PA, Marinis JM, Lich JD, Berger SB, Chirala A, Cox JA, et al. Identification of a RIP1 kinase inhibitor clinical candidate (GSK3145095) for the treatment of pancreatic cancer. ACS Med Chem Lett. 2019;10:857\u201362.","journal-title":"ACS Med Chem Lett"},{"key":"6370_CR130","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1021\/acs.jmedchem.5b01898","volume":"59","author":"PA Harris","year":"2016","unstructured":"Harris PA, King BW, Bandyopadhyay D, Berger SB, Campobasso N, Capriotti CA, et al. DNA-encoded library screening identifies benzo[b][1,4]oxazepin-4-ones as highly potent and monoselective receptor interacting protein 1 kinase inhibitors. J Med Chem. 2016;59:2163\u201378.","journal-title":"J Med Chem"},{"key":"6370_CR131","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s11095-021-03059-z","volume":"38","author":"DJ Tompson","year":"2021","unstructured":"Tompson DJ, Whitaker M, Pan R, Johnson G, Fuller T, McKenzie L, et al. Development of a prototype, once-daily, modified-release formulation for the short half-life RIPK1 inhibitor GSK2982772. Pharm Res. 2021;38:1235\u201345.","journal-title":"Pharm Res"},{"key":"6370_CR132","doi-asserted-by":"publisher","first-page":"e00377","DOI":"10.1002\/prp2.377","volume":"5","author":"JN Finger","year":"2017","unstructured":"Finger JN, Brusq JM, Campobasso N, Cook MN, Deutsch J, Haag H, et al. Identification of an antibody-based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues. Pharmacol Res Perspect. 2017;5:e00377.","journal-title":"Pharmacol Res Perspect"},{"key":"6370_CR133","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/cpt.1852","volume":"108","author":"K Weisel","year":"2020","unstructured":"Weisel K, Berger S, Papp K, Maari C, Krueger JG, Scott N, et al. Response to inhibition of receptor-interacting protein kinase 1 (RIPK1) in active plaque psoriasis: a randomized placebo-controlled study. Clin Pharm Ther. 2020;108:808\u201316.","journal-title":"Clin Pharm Ther"},{"key":"6370_CR134","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13075-021-02468-0","volume":"23","author":"K Weisel","year":"2021","unstructured":"Weisel K, Berger S, Thorn K, Taylor PC, Peterfy C, Siddall H, et al. A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis. Arthritis Res Ther. 2021;23:85.","journal-title":"Arthritis Res Ther"},{"key":"6370_CR135","doi-asserted-by":"publisher","first-page":"e000680","DOI":"10.1136\/bmjgast-2021-000680","volume":"8","author":"K Weisel","year":"2021","unstructured":"Weisel K, Scott N, Berger S, Wang S, Brown K, Powell M, et al. A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis. BMJ Open Gastroenterol. 2021;8:e000680.","journal-title":"BMJ Open Gastroenterol"},{"key":"6370_CR136","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s13318-020-00652-2","volume":"46","author":"DJ Tompson","year":"2021","unstructured":"Tompson DJ, Davies C, Scott NE, Cannons EP, Kostapanos M, Gross AS, et al. Comparison of the pharmacokinetics of RIPK1 inhibitor GSK2982772 in healthy Western and Japanese subjects. Eur J Drug Metab Pharmacokinet. 2021;46:71\u201383.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"6370_CR137","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11095-021-03124-7","volume":"39","author":"D Tompson","year":"2022","unstructured":"Tompson D, Whitaker M, Pan R, Johnson G, Fuller T, Zann V, et al. Development of a once-daily modified-release formulation for the short half-life RIPK1 inhibitor GSK2982772 using DiffCORE technology. Pharm Res. 2022;39:153\u201365.","journal-title":"Pharm Res"},{"key":"6370_CR138","doi-asserted-by":"publisher","first-page":"113751","DOI":"10.1016\/j.bcp.2019.113751","volume":"172","author":"H Lu","year":"2020","unstructured":"Lu H, Li H, Fan C, Qi Q, Yan Y, Wu Y, et al. RIPK1 inhibitor ameliorates colitis by directly maintaining intestinal barrier homeostasis and regulating following IECs-immuno crosstalk. Biochem Pharm. 2020;172:113751.","journal-title":"Biochem Pharm"},{"key":"6370_CR139","doi-asserted-by":"publisher","first-page":"e202114922","DOI":"10.1002\/anie.202114922","volume":"61","author":"X Yang","year":"2022","unstructured":"Yang X, Lu H, Xie H, Zhang B, Nie T, Fan C, et al. Potent and selective RIPK1 inhibitors targeting dual-pockets for the treatment of systemic inflammatory response syndrome and sepsis. Angew Chem Int Ed Engl. 2022;61:e202114922.","journal-title":"Angew Chem Int Ed Engl"},{"key":"6370_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1735-6","volume":"10","author":"J Hou","year":"2019","unstructured":"Hou J, Ju J, Zhang Z, Zhao C, Li Z, Zheng J, et al. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis. Cell Death Dis. 2019;10:493.","journal-title":"Cell Death Dis"},{"key":"6370_CR141","doi-asserted-by":"publisher","first-page":"114036","DOI":"10.1016\/j.ejmech.2021.114036","volume":"228","author":"Z Li","year":"2022","unstructured":"Li Z, Hao Y, Yang C, Yang Q, Wu S, Ma H, et al. Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity. Eur J Med Chem. 2022;228:114036.","journal-title":"Eur J Med Chem"},{"key":"6370_CR142","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/cpt.1615","volume":"107","author":"HW Grievink","year":"2020","unstructured":"Grievink HW, Heuberger J, Huang F, Chaudhary R, Birkhoff WAJ, Tonn GR, et al. DNL104, a centrally penetrant RIPK1 inhibitor, inhibits RIP1 kinase phosphorylation in a randomized phase I ascending dose study in healthy volunteers. Clin Pharm Ther. 2020;107:406\u201314.","journal-title":"Clin Pharm Ther"},{"key":"6370_CR143","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1111\/cts.13317","volume":"15","author":"M Vissers","year":"2022","unstructured":"Vissers M, Heuberger J, Groeneveld GJ, Oude Nijhuis J, De Deyn PP, Hadi S, et al. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: randomized, placebo-controlled, double-blind phase I\/Ib studies in healthy subjects and patients. Clin Transl Sci. 2022;15:2010\u201323.","journal-title":"Clin Transl Sci"},{"key":"6370_CR144","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1111\/cts.13580","volume":"16","author":"J Lickliter","year":"2023","unstructured":"Lickliter J, Wang S, Zhang W, Zhu H, Wang J, Zhao C, et al. A phase I randomized, double-blinded, placebo-controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects. Clin Transl Sci. 2023;16:1691\u2013703.","journal-title":"Clin Transl Sci"},{"key":"6370_CR145","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41418-020-00629-3","volume":"28","author":"M Kist","year":"2021","unstructured":"Kist M, K\u0151m\u0171ves LG, Goncharov T, Dugger DL, Yu C, Roose-Girma M, et al. Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. Cell Death Differ. 2021;28:985\u20131000.","journal-title":"Cell Death Differ"},{"key":"6370_CR146","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41418-019-0347-0","volume":"27","author":"S Patel","year":"2020","unstructured":"Patel S, Webster JD, Varfolomeev E, Kwon YC, Cheng JH, Zhang J, et al. RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases. Cell Death Differ. 2020;27:161\u201375.","journal-title":"Cell Death Differ"},{"key":"6370_CR147","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/JLB.3MA1219-398R","volume":"107","author":"JD Webster","year":"2020","unstructured":"Webster JD, Kwon YC, Park S, Zhang H, Corr N, Ljumanovic N, et al. RIP1 kinase activity is critical for skin inflammation but not for viral propagation. J Leukoc Biol. 2020;107:941\u201352.","journal-title":"J Leukoc Biol"},{"key":"6370_CR148","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood.2022017262","volume":"141","author":"X Yu","year":"2022","unstructured":"Yu X, Ma H, Li B, Ji Y, Du Y, Liu S, et al. A Novel RIPK1 inhibitor reduces GVHD in mice via a non-immunosuppressive mechanism that restores intestinal homeostasis. Blood. 2022;141:1070\u201386.","journal-title":"Blood"},{"key":"6370_CR149","doi-asserted-by":"publisher","first-page":"14957","DOI":"10.1021\/acs.jmedchem.2c01478","volume":"65","author":"Y Sun","year":"2022","unstructured":"Sun Y, Xu L, Shao H, Quan D, Mo Z, Wang J, et al. Discovery of a trifluoromethoxy cyclopentanone benzothiazole receptor-interacting protein kinase 1 inhibitor as the treatment for Alzheimer\u2019s Disease. J Med Chem. 2022;65:14957\u201369.","journal-title":"J Med Chem"},{"key":"6370_CR150","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41420-020-0240-0","volume":"6","author":"H Brito","year":"2020","unstructured":"Brito H, Marques V, Afonso MB, Brown DG, B\u00f6rjesson U, Selmi N, et al. Phenotypic high-throughput screening platform identifies novel chemotypes for necroptosis inhibition. Cell Death Discov. 2020;6:6.","journal-title":"Cell Death Discov"},{"key":"6370_CR151","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1021\/acs.jmedchem.6b01196","volume":"60","author":"Y Ren","year":"2017","unstructured":"Ren Y, Su Y, Sun L, He S, Meng L, Liao D, et al. Discovery of a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) for the treatment of systemic inflammatory response syndrome. J Med Chem. 2017;60:972\u201386.","journal-title":"J Med Chem"},{"key":"6370_CR152","doi-asserted-by":"publisher","first-page":"175381","DOI":"10.1016\/j.ejphar.2022.175381","volume":"937","author":"YS Zeng","year":"2022","unstructured":"Zeng YS, Peng J, Gao XF, Tian D, Zhan W, Liu J, et al. A novel gut-restricted RIPK1 inhibitor, SZ-15, ameliorates DSS-induced ulcerative colitis. Eur J Pharm. 2022;937:175381.","journal-title":"Eur J Pharm"},{"key":"6370_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12788-4","volume":"7","author":"C Delehouz\u00e9","year":"2017","unstructured":"Delehouz\u00e9 C, Leverrier-Penna S, Le Cann F, Comte A, Jacquard-Fevai M, Delalande O, et al. 6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury. Sci Rep. 2017;7:12931.","journal-title":"Sci Rep."},{"key":"6370_CR154","doi-asserted-by":"publisher","first-page":"6761","DOI":"10.1021\/cr300410v","volume":"113","author":"SB Bharate","year":"2013","unstructured":"Bharate SB, Sawant SD, Singh PP, Vishwakarma RA. Kinase inhibitors of marine origin. Chem Rev. 2013;113:6761\u2013815.","journal-title":"Chem Rev"},{"key":"6370_CR155","doi-asserted-by":"publisher","first-page":"112337","DOI":"10.1016\/j.ejmech.2020.112337","volume":"201","author":"M Benchekroun","year":"2020","unstructured":"Benchekroun M, Ermolenko L, Tran MQ, Vagneux A, Nedev H, Delehouz\u00e9 C, et al. Discovery of simplified benzazole fragments derived from the marine benzosceptrin B as necroptosis inhibitors involving the receptor interacting protein Kinase-1. Eur J Med Chem. 2020;201:112337.","journal-title":"Eur J Med Chem"},{"key":"6370_CR156","doi-asserted-by":"publisher","first-page":"113030","DOI":"10.1016\/j.ejmech.2020.113030","volume":"212","author":"Y Wang","year":"2021","unstructured":"Wang Y, Ma H, Huang J, Yao Z, Yu J, Zhang W, et al. Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors. Eur J Med Chem. 2021;212:113030.","journal-title":"Eur J Med Chem"},{"key":"6370_CR157","doi-asserted-by":"publisher","first-page":"31268","DOI":"10.1074\/jbc.M113.462341","volume":"288","author":"WJ Kaiser","year":"2013","unstructured":"Kaiser WJ, Sridharan H, Huang C, Mandal P, Upton JW, Gough PJ, et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem. 2013;288:31268\u201379.","journal-title":"J Biol Chem"},{"key":"6370_CR158","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.molcel.2014.10.021","volume":"56","author":"P Mandal","year":"2014","unstructured":"Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014;56:481\u201395.","journal-title":"Mol Cell"},{"key":"6370_CR159","doi-asserted-by":"publisher","first-page":"109262","DOI":"10.1016\/j.intimp.2022.109262","volume":"112","author":"CH Xu","year":"2022","unstructured":"Xu CH, Wang JN, Suo XG, Ji ML, He XY, Chen X, et al. RIPK3 inhibitor-AZD5423 alleviates acute kidney injury by inhibiting necroptosis and inflammation. Int Immunopharmacol. 2022;112:109262.","journal-title":"Int Immunopharmacol"},{"key":"6370_CR160","doi-asserted-by":"publisher","first-page":"6665","DOI":"10.1021\/acs.jmedchem.9b00611","volume":"62","author":"H Zhang","year":"2019","unstructured":"Zhang H, Xu L, Qin X, Chen X, Cong H, Hu L, et al. N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) analogues as novel necroptosis inhibitors by targeting receptor-interacting protein kinase 3 (RIPK3): synthesis, structure-activity relationships, and in vivo efficacy. J Med Chem. 2019;62:6665\u201381.","journal-title":"J Med Chem"},{"key":"6370_CR161","doi-asserted-by":"publisher","first-page":"1041117","DOI":"10.3389\/fphar.2022.1041117","volume":"13","author":"B Hou","year":"2022","unstructured":"Hou B, Liu M, Chen Y, Ni W, Suo X, Xu Y, et al. Cpd-42 protects against calcium oxalate nephrocalcinosis-induced renal injury and inflammation by targeting RIPK3-mediated necroptosis. Front Pharm. 2022;13:1041117.","journal-title":"Front Pharm"},{"key":"6370_CR162","first-page":"1","volume":"50","author":"HH Park","year":"2018","unstructured":"Park HH, Park SY, Mah S, Park JH, Hong SS, Hong S, et al. HS-1371, a novel kinase inhibitor of RIP3-mediated necroptosis. Exp Mol Med. 2018;50:1\u201315.","journal-title":"Exp Mol Med"},{"key":"6370_CR163","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/cdd.2015.70","volume":"23","author":"DA Rodriguez","year":"2016","unstructured":"Rodriguez DA, Weinlich R, Brown S, Guy C, Fitzgerald P, Dillon CP, et al. Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis. Cell Death Differ. 2016;23:76\u201388.","journal-title":"Cell Death Differ"},{"key":"6370_CR164","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.chom.2021.05.009","volume":"29","author":"H Koehler","year":"2021","unstructured":"Koehler H, Cotsmire S, Zhang T, Balachandran S, Upton JW, Langland J, et al. Vaccinia virus E3 prevents sensing of Z-RNA to block ZBP1-dependent necroptosis. Cell Host Microbe. 2021;29:1266\u201376.e5.","journal-title":"Cell Host Microbe"},{"key":"6370_CR165","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41586-022-04974-w","volume":"607","author":"R de Reuver","year":"2022","unstructured":"de Reuver R, Verdonck S, Dierick E, Nemegeer J, Hessmann E, Ahmad S, et al. ADAR1 prevents autoinflammation by suppressing spontaneous ZBP1 activation. Nature. 2022;607:784\u201389.","journal-title":"Nature"},{"key":"6370_CR166","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-022-04753-7","volume":"606","author":"T Zhang","year":"2022","unstructured":"Zhang T, Yin C, Fedorov A, Qiao L, Bao H, Beknazarov N, et al. ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. Nature. 2022;606:594\u2013602.","journal-title":"Nature"},{"key":"6370_CR167","doi-asserted-by":"publisher","first-page":"e45737","DOI":"10.15252\/embr.201845737","volume":"19","author":"PH Wang","year":"2018","unstructured":"Wang PH, Ye ZW, Deng JJ, Siu KL, Gao WW, Chaudhary V, et al. Inhibition of AIM2 inflammasome activation by a novel transcript isoform of IFI16. EMBO Rep. 2018;19:e45737.","journal-title":"EMBO Rep"},{"key":"6370_CR168","doi-asserted-by":"publisher","first-page":"102696","DOI":"10.1016\/j.jbc.2022.102696","volume":"298","author":"W Liu","year":"2022","unstructured":"Liu W, Yang J, Fang S, Jiao C, Gao J, Zhang A, et al. Spirodalesol analog 8A inhibits NLRP3 inflammasome activation and attenuates inflammatory disease by directly targeting adaptor protein ASC. J Biol Chem. 2022;298:102696.","journal-title":"J Biol Chem"},{"key":"6370_CR169","doi-asserted-by":"publisher","first-page":"eaar6689","DOI":"10.1126\/sciimmunol.aar6689","volume":"3","author":"G Sollberger","year":"2018","unstructured":"Sollberger G, Choidas A, Burn GL, Habenberger P, Di Lucrezia R, Kordes S, et al. Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. Sci Immunol. 2018;3:eaar6689.","journal-title":"Sci Immunol"},{"key":"6370_CR170","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/0002-9343(90)90534-K","volume":"88","author":"C Wright","year":"1990","unstructured":"Wright C, Moore RD. Disulfiram treatment of alcoholism. Am J Med. 1990;88:647\u201355.","journal-title":"Am J Med"},{"key":"6370_CR171","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41590-020-0669-6","volume":"21","author":"JJ Hu","year":"2020","unstructured":"Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol. 2020;21:736\u201345.","journal-title":"Nat Immunol"},{"key":"6370_CR172","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1126\/science.abb9818","volume":"369","author":"F Humphries","year":"2020","unstructured":"Humphries F, Shmuel-Galia L, Ketelut-Carneiro N, Li S, Wang B, Nemmara VV, et al. Succination inactivates gasdermin D and blocks pyroptosis. Science. 2020;369:1633\u201337.","journal-title":"Science"},{"key":"6370_CR173","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cell.2011.11.031","volume":"148","author":"L Sun","year":"2012","unstructured":"Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148:213\u201327.","journal-title":"Cell"},{"key":"6370_CR174","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","volume":"8","author":"X Xie","year":"2023","unstructured":"Xie X, Yu TT, Li X, Zhang N, Foster LJ, Peng C, et al. Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials. Signal Trans Target Ther. 2023;8:335.","journal-title":"Signal Trans Target Ther"},{"key":"6370_CR175","doi-asserted-by":"publisher","first-page":"115338","DOI":"10.1016\/j.bcp.2022.115338","volume":"206","author":"W Yang","year":"2022","unstructured":"Yang W, Tao K, Wang Y, Huang Y, Duan C, Wang T, et al. Necrosulfonamide ameliorates intestinal inflammation via inhibiting GSDMD-medicated pyroptosis and MLKL-mediated necroptosis. Biochem Pharm. 2022;206:115338.","journal-title":"Biochem Pharm"},{"key":"6370_CR176","doi-asserted-by":"publisher","first-page":"108010","DOI":"10.1016\/j.pharmthera.2021.108010","volume":"232","author":"S Christgen","year":"2022","unstructured":"Christgen S, Tweedell RE, Kanneganti TD. Programming inflammatory cell death for therapy. Pharm Ther. 2022;232:108010.","journal-title":"Pharm Ther"},{"key":"6370_CR177","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jhep.2020.09.029","volume":"74","author":"C Frenette","year":"2021","unstructured":"Frenette C, Kayali Z, Mena E, Mantry PS, Lucas KJ, Neff G, et al. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. J Hepatol. 2021;74:274\u201382.","journal-title":"J Hepatol"},{"key":"6370_CR178","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/ana.26173","volume":"90","author":"C Xu","year":"2021","unstructured":"Xu C, Zhang S, Gong Y, Nao J, Shen Y, Tan B, et al. Subicular caspase-1 contributes to pharmacoresistance in temporal lobe epilepsy. Ann Neurol. 2021;90:377\u201390.","journal-title":"Ann Neurol"},{"key":"6370_CR179","doi-asserted-by":"publisher","first-page":"103843","DOI":"10.1016\/j.ebiom.2022.103843","volume":"76","author":"Y Fang","year":"2022","unstructured":"Fang Y, Wang X, Lu J, Shi H, Huang L, Shao A, et al. Inhibition of caspase-1-mediated inflammasome activation reduced blood coagulation in cerebrospinal fluid after subarachnoid haemorrhage. EBioMedicine. 2022;76:103843.","journal-title":"EBioMedicine"},{"key":"6370_CR180","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00395-018-0692-z","volume":"113","author":"JP Audia","year":"2018","unstructured":"Audia JP, Yang XM, Crockett ES, Housley N, Haq EU, O\u2019Donnell K, et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y(12) receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. Basic Res Cardiol. 2018;113:32.","journal-title":"Basic Res Cardiol"},{"key":"6370_CR181","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/sj.bjp.0703629","volume":"131","author":"G Mathiak","year":"2000","unstructured":"Mathiak G, Grass G, Herzmann T, Luebke T, Zetina CC, Boehm SA, et al. Caspase-1-inhibitor ac-YVAD-cmk reduces LPS-lethality in rats without affecting haematology or cytokine responses. Br J Pharm. 2000;131:383\u20136.","journal-title":"Br J Pharm"},{"key":"6370_CR182","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1165\/rcmb.2018-0192OC","volume":"61","author":"F Dapaah-Siakwan","year":"2019","unstructured":"Dapaah-Siakwan F, Zambrano R, Luo S, Duncan MR, Kerr N, Donda K, et al. Caspase-1 inhibition attenuates hyperoxia-induced lung and brain injury in neonatal mice. Am J Respir Cell Mol Biol. 2019;61:341\u201354.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"6370_CR183","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.4049\/jimmunol.1600035","volume":"197","author":"MJ Primiano","year":"2016","unstructured":"Primiano MJ, Lefker BA, Bowman MR, Bree AG, Hubeau C, Bonin PD, et al. Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation. J Immunol. 2016;197:2421\u201333.","journal-title":"J Immunol"},{"key":"6370_CR184","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jid.2019.05.025","volume":"140","author":"AM Carvalho","year":"2020","unstructured":"Carvalho AM, Novais FO, Paix\u00e3o CS, de Oliveira CI, Machado PRL, Carvalho LP, et al. Glyburide, a NLRP3 inhibitor, decreases inflammatory response and is a candidate to reduce pathology in Leishmania braziliensis infection. J Invest Dermatol. 2020;140:246\u201349.e2.","journal-title":"J Invest Dermatol"},{"key":"6370_CR185","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1042\/CS20160090","volume":"130","author":"S Robertson","year":"2016","unstructured":"Robertson S, Mart\u00ednez GJ, Payet CA, Barraclough JY, Celermajer DS, Bursill C, et al. Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clin Sci. 2016;130:1237\u201346.","journal-title":"Clin Sci"},{"key":"6370_CR186","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/all.15164","volume":"77","author":"LP Lunding","year":"2022","unstructured":"Lunding LP, Skouras DB, Vock C, Dinarello CA, Wegmann M. The NLRP3 inflammasome inhibitor, OLT1177(\u00ae), ameliorates experimental allergic asthma in mice. Allergy. 2022;77:1035\u201338.","journal-title":"Allergy"},{"key":"6370_CR187","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01988-x","volume":"17","author":"R Sun","year":"2020","unstructured":"Sun R, Peng M, Xu P, Huang F, Xie Y, Li J, et al. Low-density lipoprotein receptor (LDLR) regulates NLRP3-mediated neuronal pyroptosis following cerebral ischemia\/reperfusion injury. J Neuroinflammation. 2020;17:330.","journal-title":"J Neuroinflammation"},{"key":"6370_CR188","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1042\/CS20160645","volume":"131","author":"N Irrera","year":"2017","unstructured":"Irrera N, Vaccaro M, Bitto A, Pallio G, Pizzino G, Lentini M, et al. BAY 11-7082 inhibits the NF-\u03baB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis. Clin Sci (Lond). 2017;131:487\u201398.","journal-title":"Clin Sci (Lond)"},{"key":"6370_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04947-6","volume":"9","author":"H He","year":"2018","unstructured":"He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. 2018;9:2550.","journal-title":"Nat Commun"},{"key":"6370_CR190","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2018.10.006","volume":"34","author":"W Wang","year":"2018","unstructured":"Wang W, Marinis JM, Beal AM, Savadkar S, Wu Y, Khan M, et al. RIP1 Kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer. Cancer cell. 2018;34:757\u201374.e7.","journal-title":"Cancer cell"},{"key":"6370_CR191","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1021\/acs.jmedchem.6b01751","volume":"60","author":"PA Harris","year":"2017","unstructured":"Harris PA, Berger SB, Jeong JU, Nagilla R, Bandyopadhyay D, Campobasso N, et al. Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases. J Med Chem. 2017;60:1247\u201361.","journal-title":"J Med Chem"},{"key":"6370_CR192","doi-asserted-by":"publisher","first-page":"e00365","DOI":"10.1002\/prp2.365","volume":"5","author":"K Weisel","year":"2017","unstructured":"Weisel K, Scott NE, Tompson DJ, Votta BJ, Madhavan S, Povey K, et al. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers. Pharm Res Perspect. 2017;5:e00365.","journal-title":"Pharm Res Perspect"},{"key":"6370_CR193","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1021\/ml400382p","volume":"4","author":"PA Harris","year":"2013","unstructured":"Harris PA, Bandyopadhyay D, Berger SB, Campobasso N, Capriotti CA, Cox JA, et al. Discovery of small molecule RIP1 kinase inhibitors for the treatment of pathologies associated with necroptosis. ACS Med Chem Lett. 2013;4:1238\u201343.","journal-title":"ACS Med Chem Lett"},{"key":"6370_CR194","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/cdd.2012.133","volume":"20","author":"A Degterev","year":"2013","unstructured":"Degterev A, Maki JL, Yuan J. Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase. Cell Death Differ. 2013;20:366.","journal-title":"Cell Death Differ"},{"key":"6370_CR195","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jhep.2019.11.008","volume":"72","author":"A Majdi","year":"2020","unstructured":"Majdi A, Aoudjehane L, Ratziu V, Islam T, Afonso MB, Conti F, et al. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. J Hepatol. 2020;72:627\u201335.","journal-title":"J Hepatol"},{"key":"6370_CR196","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09019-w","volume":"12","author":"C Delehouz\u00e9","year":"2022","unstructured":"Delehouz\u00e9 C, Comte A, Leon-Icaza SA, Cougoule C, Hauteville M, Goekjian P, et al. Nigratine as dual inhibitor of necroptosis and ferroptosis regulated cell death. Sci Rep. 2022;12:5118.","journal-title":"Sci Rep."},{"key":"6370_CR197","doi-asserted-by":"crossref","unstructured":"Yoshikawa M, Saitoh M, Katoh T, Seki T, Bigi SV, Shimizu Y, et al. Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine derivatives as potent, orally available, and brain-penetrating receptor interacting protein 1 (RIP1) kinase inhibitors: analysis of structure-kinetic relationships. J Med Chem. 2018;61:2384\u2013409.","DOI":"10.1021\/acs.jmedchem.7b01647"},{"key":"6370_CR198","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03994-0","volume":"12","author":"T Delanghe","year":"2021","unstructured":"Delanghe T, Huyghe J, Lee S, Priem D, Van Coillie S, Gilbert B, et al. Antioxidant and food additive BHA prevents TNF cytotoxicity by acting as a direct RIPK1 inhibitor. Cell Death Dis. 2021;12:699.","journal-title":"Cell Death Dis"},{"key":"6370_CR199","doi-asserted-by":"publisher","first-page":"114194","DOI":"10.1016\/j.ejmech.2022.114194","volume":"232","author":"Y Jiao","year":"2022","unstructured":"Jiao Y, Nan J, Mu B, Zhang Y, Zhou N, Yang S, et al. Discovery of a novel and potent inhibitor with differential species-specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis. Eur J Med Chem. 2022;232:114194.","journal-title":"Eur J Med Chem"},{"key":"6370_CR200","doi-asserted-by":"publisher","first-page":"153019","DOI":"10.1016\/j.phymed.2019.153019","volume":"63","author":"J Kim","year":"2019","unstructured":"Kim J, Ahn H, Han BC, Shin H, Kim JC, Jung EM, et al. Obovatol inhibits NLRP3, AIM2, and non-canonical inflammasome activation. Phytomedicine. 2019;63:153019.","journal-title":"Phytomedicine"},{"key":"6370_CR201","doi-asserted-by":"publisher","first-page":"e004763","DOI":"10.1136\/jitc-2022-004763","volume":"10","author":"T Lv","year":"2022","unstructured":"Lv T, Xiong X, Yan W, Liu M, Xu H, He Q. Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression. J Immunother Cancer. 2022;10:e004763.","journal-title":"J Immunother Cancer"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06370-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06370-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06370-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T01:02:21Z","timestamp":1703120541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06370-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":201,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6370"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06370-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"assertion":[{"value":"4 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This review did not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"851"}}